ASCO: UT MD Anderson spotlights emerging precision therapies for rare and difficult-to-treat cancers
ABSTRACTS: 8510, 8008, 6009, 4520
Researchers at The University of Texas MD Anderson Cancer Center will present new findings at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting showcasing innovative targeted therapies for several rare and hard-to-treat cancers. Presentations feature precision treatments with promising early results across multiple tumor types, including lung cancer, adenoid cystic carcinoma...
Tumor markers in rare appendiceal cancer may predict treatment outcomes
Researchers monitored levels of common blood markers before and after surgery to remove cancer
Study found...
New simulation framework DKOsim advances CRISPR-based gene to gene interaction research
Double-CRISPR Knockout Simulation (DKOsim) is a computer-based “virtual lab” that simulates genomic experiments Studying...
Low testosterone levels may be associated with increased risk of prostate cancer progression during surveillance
Study found men with low testosterone levels were associated with a 60% higher likelihood that prostate cancer managed on active surveillance would progress to a more aggressive state over time
Research challenges the long-held belief that high testosterone fuels early-stage prostate cancer growth, suggesting instead that low testosterone may be associated...
Mutation predicts chemotherapy resistance and better responses to immunotherapy in advanced bladder cancer
Researchers studied the KDM6A gene, which is altered in about 26% of advanced bladder cancers
Tumors with KDM6A mutations did not respond well...
Immunotherapy combination does not improve outcomes for patients with advanced anal cancer
Phase II ETCTN trial found ipilimumab plus nivolumab did not improve outcomes over nivolumab alone in...
Targeted therapy plus immunotherapy improved outcomes in advanced metastatic colorectal cancer
Phase III COMMIT trial evaluated better first-line options for patients with dMMR/MSI-H metastatic colorectal cancer
The study...
Study identifies target for disease hyper progression after immunotherapy in kidney cancer
Researchers find that cancer cells mimic myeloid cells to hide from the immune system and promote disease hyper progression after immunotherapy...
HER2-targeted therapy shows promising results in rare bile duct cancers
HER2-positive metastatic biliary tract cancer (BTC) is a rare and aggressive cancer with limited treatment options
Final results from the...
Researchers identify rare mutation that predicts strong immunotherapy response in colorectal cancer
A specific subset of POLE gene mutation, called loss-of-proofreading (LOP) mutations, makes colorectal tumors highly responsive to immunotherapy...
MD Anderson experts spotlight key immunotherapy advances at 2025 SITC Annual Meeting
Major themes include strategies to reprogram the tumor microenvironment and prevent cancer before it starts
New insights from AI-based imaging...
Comprehensive molecular profiling of renal medullary carcinoma identifies TROP2 as a promising therapeutic target
Researchers at The University of Texas MD Anderson Cancer Center, in collaboration with BostonGene, conducted the largest and most comprehensive...
New oral therapy shows early signs of safety and effectiveness in patients with advanced, treatment-resistant prostate cancer
Trial shows promising early results for HLD-0915, a first-in-class regulated induced proximity targeting chimera (RIPTAC) treatment
Metastatic...
ESMO 2025: Dual targeted therapy shows promise in previously treated advanced kidney cancer patients
Study found patients treated with combination of lenvatinib and everolimus lived longer without disease progression
First head-to-head study...
ESMO 2025: Trial results show belzutifan shrinks rare neuroendocrine tumors and improves symptoms in patients
Pheochromocytoma and paraganglioma (PPGL) are rare, hard-to-treat neuroendocrine tumors that form in the adrenal glands or in the extra-adrenal...